|
1
|
Gavril OI, Arhire LI, Gavrilescu O, Dranga M, Barboi O, Gavril RS, Popescu R, Cijevschi Prelipcean C, Trifan AV, Mihai C. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response. Medicina (Kaunas) 2021; 57:medicina57111153. [PMID: 34833371 PMCID: PMC8618282 DOI: 10.3390/medicina57111153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Revised: 10/20/2021] [Accepted: 10/21/2021] [Indexed: 02/05/2023]
Abstract
Background and Objectives: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). Materials and Methods:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. Results: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. Conclusions: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution.
Collapse
Affiliation(s)
- Oana Irina Gavril
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Lidia Iuliana Arhire
- Department of Medical Specialties (II), Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700111 Iași, Romania;
| | - Otilia Gavrilescu
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Mihaela Dranga
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Oana Barboi
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Radu Sebastian Gavril
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
- Correspondence: ; Tel.: +40-74-040-4797
| | - Roxana Popescu
- Department of Medical Genetics, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700111 Iași, Romania;
| | - Cristina Cijevschi Prelipcean
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Anca-Victorita Trifan
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| | - Catalina Mihai
- Department of Medical Specialties (I), Faculty of Medicine, “Grigore T. Popa” Universityof Medicine and Pharmacy, 700111 Iași, Romania; (O.I.G.); (O.G.); (M.D.); (O.B.); (C.C.P.); (A.-V.T.); (C.M.)
| |
Collapse
|